×
About 4,475 results

ALLMedicine™ Hypokalemia Center

Research & Reviews  1,060 results

Eyelid ptosis and muscle weakness in a child with Kawasaki disease: a case report.
https://doi.org/10.1186/s12887-021-02979-4 10.1161/CIR.0000000000000484 10.1097/INF.0b013e3181950b64 10.1016/S0387-7604(85)80120-0 10.1016/0887-8994(90)90048-6 10.1007/s002470050665 10.1007/s12098-015-1709-3 10.1007/s12098-019-03009-z 10.1007/s00296-009-1154-6 10.1159/000357258
BMC Pediatrics; Lin Y, Wang L et. al.

Nov 29th, 2021 - Kawasaki disease (KD) is an acute febrile vasculitis that often occurs in children under 5 years. Ptosis and muscle weakness associated with KD are rarely documented. We present a case of KD with eyelid ptosis and muscle weakness in a 3-year-old b...

Evaluation of Routine Postoperative Labs Following Robotic Assisted Partial Nephrectomy...
https://doi.org/10.1016/j.urology.2021.11.012
Urology Myers AA, Geldmaker LE et. al.

Nov 25th, 2021 - To evaluate predictors of abnormal routine postoperative day 1 (POD1) labs in patients with normal pre-operative renal function following robotic assisted partial nephrectomy (RAPN) and the associated clinical outcomes of these lab results. We ana...

Acquired autoimmune Bartter syndrome in a patient with primary hypothyroidism.
https://doi.org/10.1007/s00296-021-05042-8
Rheumatology International; Nasir N, Mohanty D et. al.

Nov 21st, 2021 - We describe an unusual clinical presentation of autoimmune Bartter syndrome in a patient with primary hypothyroidism. A 65-year-old female patient was admitted with neuromuscular weakness associated with hypokalemia and metabolic alkalosis. She ha...

Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible ...
https://doi.org/10.1002/cncr.34014
Cancer Katzenstein HM, Malogolowkin MH et. al.

Nov 12th, 2021 - The Children's Oncology Group (COG) adopted cisplatin, 5-flourouracil, and vincristine (C5V) as standard therapy after the INT-0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin and doxorubici...

Atorvastatin does not ameliorate nephrogenic diabetes insipidus induced by lithium or p...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582289
Physiological Reports; Thomsen ML, Grønkjaer C et. al.

Nov 12th, 2021 - Acquired forms of nephrogenic diabetes insipidus (NDI) include lithium (Li)-induced and hypokalemia-induced NDI. Both forms are associated with AQP2 downregulation and collecting duct (CD) cellular remodeling. Statins are cholesterol-lowering drug...

see more →

Guidelines  1 results

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Drugs  488 results see all →

Clinicaltrials.gov  18 results

Diuretic Tuner Clinical Decision Support
https://clinicaltrials.gov/ct2/show/NCT04759274

Oct 28th, 2021 - Study Population: 30 subjects with signs of hypervolemia and either nephrotic syndrome or chronic kidney disease 4 to 5. Study Intervention: This is a nonrandomized, uncontrolled trial. The Diuretic Tuner mobile device application will be deployed...

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03574363

Oct 4th, 2021 - The study will enroll up to 165 patients, randomized in a 1:1:1 ratio to 1 of 3 treatment groups (55 patients in each group): KBP-5074 0.25 mg once daily (QD), KBP-5074 0.5 mg QD, or placebo QD. Randomization will be stratified to balance enrollme...

Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis
https://clinicaltrials.gov/ct2/show/NCT03814343

Sep 28th, 2021 - Introduction Onychomycosis caused by non-dermatophyte molds (NDMs) have become more common in clinical practice, particularly in tropical and subtropical area. With worldwide prevalence as high as 10-24% for nail infection, more recent studies hav...

Impact of Long-term Serum Magnesium and Potassium Levels Optimization and Multifactorial Adherence Intervention on the Progression of Diabetic Kidney Disease.
https://clinicaltrials.gov/ct2/show/NCT04942119

Jun 28th, 2021 - Some studies showed that electrolyte homeostasis is altered in diabetic patients compared with non-diabetic patients even in normotensive patients. Serum magnesium and sodium concentrations were found to be decreased and potassium and calcium leve...

Low Potassium Content Vegetables in End-Stage Renal Disease
https://clinicaltrials.gov/ct2/show/NCT04182438

Jan 3rd, 2020 - According to the plan moderator, after the patient agrees and signs the test consent form, the patients will be randomly divided into two groups. The screening execution time of this patient is expected to be 2 weeks. After randomization into two ...

see more →

News  221 results

FDA OKs First Drug for Aggressive, Ultra-Rare Sarcoma
https://www.medpagetoday.com/hematologyoncology/othercancers/95831

Nov 23rd, 2021 - The FDA approved nab-sirolimus (Fyarro) on Tuesday for the treatment of malignant perivascular epithelioid cell tumors (PEComa), a rare and aggressive form of sarcoma. Nab-sirolimus, an albumin-bound mTOR inhibitor, is indicated for patients with ...

First CDK4/6 Inhibitor OK'd for Early, High-Risk Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/95015

Oct 13th, 2021 - The FDA approved the CDK4/6 inhibitor abemaciclib (Verzenio), in combination with standard adjuvant endocrine therapy, for certain patients with early breast cancer who are at high risk of recurrence, Eli Lilly announced. Indicated for patients wh...

Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings
https://www.onclive.com/view/carfilzomib-os-benefit-in-myeloma-highlighted-in-published-findings

Aug 17th, 2021 - Keith Stewart, MB, ChB The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) extended overall survival (OS) for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidom...

FDA OKs First Interchangeable Insulin Biosimilar
https://www.medpagetoday.com/primarycare/diabetes/93799

Jul 29th, 2021 - The FDA approved Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin product for diabetes, allowing for pharmacy-level substitution in states that allow it, the agency announced on Wednesday. "This is a momentous day fo...

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments
https://www.onclive.com/view/transplant-associated-thrombotic-microangiopathy-new-insights-emerging-treatments

Jul 22nd, 2021 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of stem cell transplants that can occur with peripherally mobilized stem cells or bone marrow-derived stem cells. TA-TMA remains a difficult complication to address, with ...

see more →

Patient Education  2 results see all →